Get the Stockscreener App
10.75
2.77%
0.29
After Hours:
10.75
Entrada Therapeutics Inc Stock (TRDA) Latest News
Entrada Therapeutics CFO sells $19,035 in stock - Investing.com
Long Term Trading Analysis for (TRDA) - Stock Traders Daily
Entrada Therapeutics stock hits 52-week low at $10.25 By Investing.com - Investing.com Australia
Entrada Therapeutics stock hits 52-week low at $10.25 - Investing.com
Entrada Therapeutics (TRDA) Expected to Announce Earnings on Wednesday - Defense World
Entrada Therapeutics stock hits 52-week low at $11.3 amid market shifts - Investing.com Canada
Brokers Offer Predictions for TRDA Q4 Earnings - Defense World
What is William Blair’s Estimate for TRDA Q1 Earnings? - Defense World
Results: Entrada Therapeutics, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - Simply Wall St
Entrada Therapeutics, Inc. Just Beat EPS By 55%: Here's What Analysts Think Will Happen Next - Yahoo Finance
Entrada Therapeutics (NASDAQ:TRDA) Releases Earnings Results, Beats Estimates By $0.69 EPS - MarketBeat
Entrada Therapeutics' (TRDA) Buy Rating Reiterated at HC Wainwright - MarketBeat
Entrada Therapeutics: Regulatory Progress and Strategic Trials Drive Buy Rating - TipRanks
Entrada Therapeutics reports Q4 EPS 3c vs. (29c) last year - TipRanks
Oppenheimer maintains Entrada stock Outperform with $30 target - Investing.com
Oppenheimer maintains Entrada stock Outperform with $30 target By Investing.com - Investing.com South Africa
Entrada Therapeutics Reports Strong 2024 Financial Results - TipRanks
Entrada Therapeutics earnings beat by $0.70, revenue fell short of estimates - Investing.com UK
Entrada Therapeutics sees cash runway into 2Q27 - TipRanks
Entrada Therapeutics, Inc. SEC 10-K Report - TradingView
Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
HC Wainwright Reiterates Buy Rating for Entrada Therapeutics (NASDAQ:TRDA) - Defense World
Allspring Global Investments Holdings LLC Lowers Stake in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Entrada Therapeutics Receives Buy Rating Amid Regulatory Progress and Promising Clinical Developments - TipRanks
FDA authorizes Entrada’s DMD drug study By Investing.com - Investing.com Australia
Optimistic Outlook on Entrada Therapeutics: FDA Lifts Hold on ENTR-601-44, Paving Way for Key Trials - TipRanks
FDA Clears Entrada Therapeutics' Early-Stage For Potential Treatment Of Duchenne Muscular Dystrophy - Benzinga
Entrada Therapeutics Says FDA Lifted Clinical Hold on ENTR-601-44; Shares Advance Premarket - Marketscreener.com
Entrada rises as FDA removes clinical hold on muscle-wasting therapy - TradingView
FDA authorizes Entrada's DMD drug study - Investing.com India
FDA authorizes Entrada’s DMD drug study - Investing.com
Entrada Therapeutics Receives FDA Approval for DMD Study - TipRanks
FDA authorizes Entrada's DMD drug study By Investing.com - Investing.com South Africa
Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44 - The Manila Times
Entrada announces FDA removal of clinical hold on ENTR-601-44 - TipRanks
H.C. Wainwright maintains $20 target on Entrada Therapeutics stock - MSN
Trading (TRDA) With Integrated Risk Controls - Stock Traders Daily
Entrada Therapeutics: Cash-Rich Innovator With Asymmetric Upside - Seeking Alpha
Entrada Therapeutics Inc.: Promising Therapeutic Potential and Favorable Valuation Amidst Risks - TipRanks
Entrada Therapeutics, Inc. (TRDA): A Cheap Biotech Stock to Invest In Now - Insider Monkey
10 Cheap Biotech Stocks to Invest in Now - Insider Monkey
How the (TRDA) price action is used to our Advantage - Stock Traders Daily
Entrada Shorted Ohio State Affiliate $20 Million Fees, Suit Says - Bloomberg Law
Entrada Therapeutics (NASDAQ:TRDA) Receives Buy Rating from HC Wainwright - MarketBeat
SG Americas Securities LLC Has $243,000 Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
BlackRock, Inc. Increases Stake in Entrada Therapeutics Inc - GuruFocus.com
Entrada Therapeutics advances Duchenne treatment study - MSN
ENTR-601-44 Trial For DMD Authorized In UK, Study Launch Expected In Q2 2025 - Nasdaq
Entrada Therapeutics Gets UK Approval for Phase 1/2 Study of Duchenne Muscular Dystrophy Treatment - Marketscreener.com
Entrada Therapeutics Advances Duchenne Muscular Dystrophy Trial - TipRanks
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy - The Manila Times
Duchenne Muscular Dystrophy Breakthrough: Entrada's Novel Treatment Advances After Promising Safety Results - StockTitan
Azenta Announces the Election of Dipal Doshi to its Board of Directors - PR Newswire
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):